Bora Pharmaceuticals Secures First Sterile Manufacturing Plant

Bora Pharmaceuticals has signed a deal to purchase Emergent BioSolutions’ sterile manufacturing plant located in Baltimore-Camden, Maryland, marking a significant step in the company's commercial expansion. Following its recent acquisition of Upsher-Smith Laboratories, a generics manufacturer based in Minnesota, earlier this year, Bora has solidified its presence in the U.S. This acquisition represents the next pivotal stage in Bora's growth strategy, aimed at expanding its capabilities in sterile drug product manufacturing and enhancing its footprint across North America.

The recently obtained 87,000 square foot facility now offers manufacturing services for sterile injectable drug products. It provides clinical and commercial non-viral aseptic filling services across four lines, which include lyophilization, vial filling, and pre-filled syringe filling. This acquisition enables Bora to expand its capabilities in drug substance and drug product manufacturing. It also enhances the services provided by Bora Biologics, the company's platform for biologics development and manufacturing.

Bobby Sheng, Chairman & CEO of Bora Group, said “This transaction not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers. We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility.”

The market for sterile injectables is expanding, projected to reach around $1.0 trillion by 2030 with an annual growth rate of 10.17% over six years, as reported by Research and Markets. Bora intends to improve the newly acquired facility significantly and assures that all current Camden site employees will have the option to stay and join the Bora workforce.